Try our beta test site

Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations

This study has been completed.
Sponsor:
Collaborators:
Bayer
Genzyme, a Sanofi Company
Onyx Pharmaceuticals
National Cancer Institute (NCI)
Georgia Institute of Technology
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00943943
First received: July 20, 2009
Last updated: March 27, 2017
Last verified: March 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 23, 2017
  Primary Completion Date: March 23, 2017 (Final data collection date for primary outcome measure)